Mikelyn Burnell, RN | |
555 St Clair River Dr, Algonac, MA 48001 | |
(810) 794-7548 | |
Not Available |
Full Name | Mikelyn Burnell |
---|---|
Gender | Female |
Speciality | Registered Nurse |
Location | 555 St Clair River Dr, Algonac, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932320454 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | 4704089301 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mikelyn Burnell, RN 2872 Harwood Dr, Kimball, MI 48074 Ph: (810) 987-6546 | Mikelyn Burnell, RN 555 St Clair River Dr, Algonac, MA 48001 Ph: (810) 794-7548 |
News Archive
News outlets explore whether employer decisions are the result of the health law or part of long-term trends, as well as how agricultural businesses are preparing for the employer mandate, now delayed until 2015.
Healthland, America's market leader of healthcare information solutions for small community and critical access hospitals, announced today it will participate in the upcoming Healthcare Information and Management Systems Society (HIMSS) conferences, The ARRA Era – Takin' HIT to the Streets, in Dallas, Dec. 4, 2009 and in Chicago, Jan. 15, 2010.
Centene Corporation (NYSE: CNC) ("Centene") announced today that it has entered into a transaction whereby Community Health Solutions of America, Inc. ("CHS") will assign its contract with the Louisiana Department of Health and Hospitals ("DHH") under the Bayou Health Shared Savings Program to Centene's wholly owned subsidiary, Louisiana Healthcare Connections, Inc. ("LHCC").
PHNS Inc. announced that it has been engaged by NorthBay Healthcare (NorthBay), Fairfield, California, to begin the process of assessing its readiness for its migration from ICD-9 to ICD-10. PHNS was awarded this Phase 1 of a multi-phase project for NorthBay.
Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.
› Verified 4 days ago